Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan
Table 2
Pharmacists answers to statements about biosimilar medicines (n = 502).
In your opinion, which statements about biosimilar medicines are accurate? a biosimilar medicine:
Adequate answer
Number of adequate answers
n (%)
Is structurally identical to its reference medicinal product
No
139 (38.4)
Is similar to a reference medicinal product that has gone off-patent
Yes
383 (67.3)
Has no meaningful differences from a reference medicinal product in terms of quality
Yes
323 (64.3)
Has no meaningful differences from a reference medicinal product in terms of safety
Yes
359 (71.5)
Has no meaningful differences from a reference medicinal product in terms of efficacy
Yes
348 (69.3)
Has the same dosage and route of administration compared to its reference medicinal product
Yes
194 (38.6)
Is a drug for which marketing authorization is granted on the sole investigation of pharmacokinetic bioequivalence with its reference medicinal product
No
383 (76.3)
Is a drug for which assessment of biosimilarity requires more comprehensive data compared to generic drugs
Yes
386 (76.9)
Requires preclinical and clinical studies
Yes
378 (75.3)
Extrapolation of indications is the authorization of a biosimilar in indications of the reference biologic in the absence of specific clinical trial/data for the biosimilar in those indications
